Saltar al contenido principal

ETHNOS_APP

Inicio • Búsqueda • Revistas • Lista 0

Anna Maria Werling

Datos Biográficos

ID7906255
NOMBREAnna Maria Werling
NOMBRESAnna Maria
APELLIDOWerling
FIRMAWERLING A M
AFILIACIONESUniversity of Zurich
ORCID0000-0001-8998-7902
VERIFICADOSí
TOTAL DE OBRAS4
TOTAL DE CITAS0
TOTAL COMO AUTOR4
TOTAL COMO EDITOR0
PRIMER AÑO DE PUBLICACIÓN2022
AÑO MÁS RECIENTE DE PUBLICACIÓN2024
ÍNDICE H0
  • Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD

    Open Access•Anna Kaiser, Anna K Kaiser et al.•ARTICLE•Frontiers in Psychiatry•2024

    Current findings indicate a potential value of self-report (BRIEF global score) and some objectively measured neurocognitive indices (CPT commission errors and hit reaction time variability) as treatment markers (of change) for MPH. However, we found a rather limited prognostic value with regard to predicting treatment response not (yet) allowing recommendation for clinical use. Baseline symptom severity was revealed as the most relevant predicto…

  • Problematic use of digital media in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder compared to controls. A meta-analysis

    Open Access•Anna Maria Werling, Sajiv Kuzhippallil et al.•ARTICLE•Journal of Behavioral Addictions•2022

  • Personalized at‐home neurofeedback compared to long‐acting methylphenidate in children with ADHD

    Open Access•Diane Purper‐Ouakil, Hilario Blasco‐Fontecilla et al.•ARTICLE•Journal of Child Psychology and…•2022

    BACKGROUND: Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13 years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children…

  • The Impact of the Covid-19 Pandemic on Mental Health Care of Children and Adolescents in Switzerland

    Open Access•Anna Maria Werling, Susanne Walitza et al.•ARTICLE•International Journal of…•2022

    For the first pandemic year, youth mental health professionals reported a large increase in the treatment demand and waiting time and a worrisome overload of treatment services

Sin obras prominentes en esta página.

  • Problematic use of digital media in children and adolescents with a diagnosis of attention-deficit/hyperactivity disorder compared to controls. A meta-analysis

    Open Access•Anna Maria Werling, Sajiv Kuzhippallil et al.•ARTICLE•Journal of Behavioral Addictions•2022

  • Personalized at‐home neurofeedback compared to long‐acting methylphenidate in children with ADHD

    Open Access•Diane Purper‐Ouakil, Hilario Blasco‐Fontecilla et al.•ARTICLE•Journal of Child Psychology and…•2022

    BACKGROUND: Neurofeedback is considered a promising intervention for the treatment of attention-deficit hyperactivity disorder (ADHD). NEWROFEED is a prospective, multicentre, randomized (3:2), reference drug-controlled trial in children with ADHD aged between 7 and 13 years. The main objective of NEWROFEED was to demonstrate the noninferiority of personalized at-home neurofeedback (NF) training versus methylphenidate in the treatment of children…

  • The Impact of the Covid-19 Pandemic on Mental Health Care of Children and Adolescents in Switzerland

    Open Access•Anna Maria Werling, Susanne Walitza et al.•ARTICLE•International Journal of…•2022

    For the first pandemic year, youth mental health professionals reported a large increase in the treatment demand and waiting time and a worrisome overload of treatment services

  • Limited usefulness of neurocognitive functioning indices as predictive markers for treatment response to methylphenidate or neurofeedback@home in children and adolescents with ADHD

    Open Access•Anna Kaiser, Anna K Kaiser et al.•ARTICLE•Frontiers in Psychiatry•2024

    Current findings indicate a potential value of self-report (BRIEF global score) and some objectively measured neurocognitive indices (CPT commission errors and hit reaction time variability) as treatment markers (of change) for MPH. However, we found a rather limited prognostic value with regard to predicting treatment response not (yet) allowing recommendation for clinical use. Baseline symptom severity was revealed as the most relevant predicto…

Medicine (3 obras) · Psychiatry (3 obras) · Psychology (3 obras) · Attention Deficit Hyperactivity Disorder (2 obras) · Electroencephalography (2 obras) · Internal Medicine (2 obras) · Methylphenidate (2 obras) · Neural and Behavioral Psychology Studies (2 obras) · Neurofeedback (2 obras) · Child and Adolescent Psychosocial and Emotional Development (1 obra)

Ethnos_APP • Proyecto Open Source • Licencia MIT • Frontend v2.0.0 • Privacidad y Cookies • Documentación de la API: api.ethnos.app/docs • Código de la API: GitHub • DOI: 10.5281/zenodo.17049435 • Código del Frontend: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae